Cardiovascular Effects of Anabolic-Androgenic Steroids in Dietary Supplements
https://doi.org/10.47529/2223-2524.2023.2.11
Abstract
Dietary supplements are regularly consumed by more than 70 % of the US population, as well as by competitive and non-competitive athletes. Anabolic-androgenic steroids (AAS) are frequently found in dietary supplements, and have the potential for multi-organ toxicity, including significant effects on the cardiovascular system. Cardiovascular toxicities of AAS include coronary artery effects, e.g. spasm, thrombosis and plaque rupture, leading to acute coronary syndromes and myocardial infarctions, as well as direct myocardial toxicity, causing left ventricular hypertrophy, fibrosis and dysfunction. Coronary and myocardial effects converge towards a common final pathway, causing heart failure, life-threatening arrhythmias and sudden cardiac death. The unregulated nature of AAS in dietary supplements has many ramifications. Both coaches and athletes should be aware that testing positive for a prohibited substance (including AAS) constitutes a potential doping violation. We advocate for improved education of the public at large regarding the potential for AAS to be included in dietary supplements, as well as its regulation by the appropriate authorities.
About the Authors
P. van der Bijl
Stellenbosch University
South Africa
South Africa
Pieter van der Bijl — BChD, PhD, Emeritus Professor and Former Head Department of Pharmacology, Faculty of Medicine and Health Sciences
7505 South Africa, Cape Town, Tygerberg, Francie van Zijl Drive
P. van der Bijl (Jr)
Kuils River Hospital
South Africa
South Africa
Pieter van der Bijl (Jr) — MD, PhD, Consultant Cardiologist, SA Endovascular, Netcare Kuils River Hospital
7580, South Africa, Cape Town, Kuils Rivier, van Riebeeck Rd, 33
References
1. Ronis M.J.J., Pedersen K.B., Watt J. Adverse Effects of Nutraceuticals and Dietary Supplements. Annu. Rev. Pharmacol. Toxicol. 2018;58:583–601. https://doi.org/10.1146/annurev-pharmtox-010617-052844
2. van der Bijl P., Tutelyan V.A. Dietary supplements containing prohibited substances. Vopr Pitan. 2013;82(6):6–13.
3. Mueller C. The regulatory status of medical foods and dietary supplements in the United States. Nutrition. 1999;15(3):249–251. https://doi.org/10.1016/s0899-9007(98)00186-5
4. National Institutes of Health. Office of Dietary Supplements. Background Information: Dietary Supplements [internet]. Available at: https://ods.od.nih.gov/factsheets/dietarysupplements-Consumer/.
5. Food and Drug Administration. Dietary Supplements [internet]. Available at: https://www.fda.gov/food/dietary-supplements
6. Tucker J., Fischer T., Upjohn L., Mazzera D., Kumar M. Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings. JAMA Netw. Open. 2018;1(6):e183337. https://doi.org/10.1001/jamanetworkopen.2018.3337
7. Delimaris I. Adverse Effects Associated with Protein Intake above the Recommended Dietary Allowance for Adults. ISRN Nutr. 2013;2013:126929. https://doi.org/10.5402/2013/126929
8. Mazzeo F. Drug abuse in elite athletes: doping in sports. Sport Science. 2016;9(2):33–41.
9. Tlili R., Zayed S., Saoudi W., Azaiez F., Hentati R., Ben Ameur Y. Adverse cardiovascular effects of doping in athletes. Tunis Med. 2019;97(11):1211–1218.
10. La Gerche A., Brosnan M.J. Cardiovascular Effects of Performance-Enhancing Drugs. Circulation. 2017;135(1):89–99. https://doi.org/10.1161/CIRCULATIONAHA.116.022535
11. Bhasin S., Storer T.W., Berman N., Callegari C., Clevenger B., Phillips J., et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N. Engl. J. Med. 1996;335(1):1–7. https://doi.org/10.1056/NEJM199607043350101
12. Geyer H., Parr M.K., Koehler K., Mareck U., Schanzer W., Thevis M. Nutritional supplements cross-contaminated and faked with doping substances. J. Mass Spectrom. 2008;43(7):892–902. https://doi.org/10.1002/jms.1452
13. Lincoff A.M., Bhasin S., Flevaris P., Mitchell L.M., Basaria S., Boden W.E., Cunningham G.R., Granger C.B., Khera M., Thompson I.M., Jr. et al. Cardiovascular Safety of TestosteroneReplacement Therapy. N Engl J Med. 2023;389:107–117. doi.org/10.1056/NEJMoa2215025
14. Sivalokanathan S., Malek L.A., Malhotra A. The Cardiac Effects of Performance-Enhancing Medications: Caffeine vs. Anabolic Androgenic Steroids. Diagnostics (Basel). 2021;11(2):324. https://doi.org/10.3390/diagnostics11020324
15. Forbes G.B., Porta C.R., Herr B.E., Griggs R.C. Sequence of changes in body composition induced by testosterone and reversal of changes after drug is stopped. JAMA. 1992;267(3):397–399.
16. Golestani R., Slart R.H., Dullaart R.P., Glaudemans A.W., Zeebregts C.J., Boersma H.H., et al. Adverse cardiovascular effects of anabolic steroids: pathophysiology imaging. Eur. J. Clin. Invest. 2012;42(7):795–803. https://doi.org/10.1111/j.1365-2362.2011.02642.x
17. Montisci M., El Mazloum R., Cecchetto G., Terranova C., Ferrara S.D., Thiene G., Basso C. Anabolic androgenic steroids abuse and cardiac death in athletes: morphological and toxicological findings in four fatal cases. Forensic Sci. Int. 2012;217(1-3):e13–18. https://doi.org/10.1016/j.forsciint.2011.10.032
18. Fineschi V., Riezzo I., Centini F., Silingardi E., Licata M., Beduschi G., Karch S.B. Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders. Int. J. Legal Med. 2007;121(1):48–53. https://doi.org/10.1007/s00414-005-0055-9
19. Thiblin I., Lindquist O., Rajs J. Cause and manner of death among users of anabolic androgenic steroids. J. Forensic Sci. 2000;45(1):16–23.
20. Hartgens F., Rietjens G., Keizer H.A., Kuipers H., Wolffenbuttel B.H. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br. J. Sports Med. 2004;38(3):253–259. https://doi.org/10.1136/bjsm.2003.000199
21. Riebe D., Fernhall B., Thompson P.D. The blood pressure response to exercise in anabolic steroid users. Med. Sci. Sports Exerc. 1992;24(6):633–637.
22. Baggish A.L., Weiner R.B., Kanayama G., Hudson J.I., Lu M.T., Hoffmann U., Pope H.G., Jr. Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use. Circulation. 2017;135(21):1991–2002. https://doi.org/10.1161/CIRCULATIONAHA.116.026945
23. Gralnick H.R., Rick M.E. Danazol increases factor VIII and factor IX in classic hemophilia and Christmas disease. N Engl J Med. 1983;308:1393–1395. https://doi.org/ 10.1056/NEJM198306093082305
24. Kluft C., Bertina R.M., Preston F.E., Malia R.G., Blamey S.L., Lowe G.D., Forbes C.D. Protein C, an anticoagulant protein, is increased in healthy volunteers and surgical patients after treatment with stanozolol. Thromb Res. 1984;33:297–304. https://doi.org/ 10.1016/0049-3848(84)90165-8
25. Gonzales R.J., Ghaffari A.A., Duckles S.P., Krause D.N. Testosterone treatment increases thromboxane function in rat cerebral arteries. Am J Physiol Heart Circ Physiol. 2005;289:H578–585. https://doi.org/ 10.1152/ajpheart.00958.2004
26. Ajayi A.A., Mathur R., Halushka P.V. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation. 1995;91:2742–2747. https://doi.org/ 10.1161/01.cir.91.11.2742
27. Sachtleben T.R., Berg K.E., Elias B.A., Cheatham J.P., Felix G.L., Hofschire P.J. The effects of anabolic steroids on myocardial structure and cardiovascular fitness. Med. Sci. Sports Exerc. 1993;25(11):1240–1245.
28. Baggish A.L., Weiner R.B., Kanayama G., Hudson J.I., Picard M.H., Hutter A.M., Jr., Pope H.G., Jr. Long-term anabolicandrogenic steroid use is associated with left ventricular dysfunction. Circ. Heart Fail. 2010;3(4):472–476. https://doi.org/10.1161/CIRCHEARTFAILURE.109.931063
29. Pereira-Junior P.P., Chaves E.A., Costa E.S.R.H., Masuda M.O., de Carvalho A.C., Nascimento J.H. Cardiac autonomic dysfunction in rats chronically treated with anabolic steroid. Eur. J. Appl. Physiol. 2006;96(5):487–494. https://doi.org/10.1007/s00421-005-0111-7
30. van der Bijl P., Bax J.J. Imaging for risk stratification of sudden cardiac death. Herzschrittmacherther Elektrophysiol. 2022;33(3):261–267. https://doi.org/10.1007/s00399-022-00884-6
31. Maior A.S., Menezes P., Pedrosa R.C., Carvalho D.P., Soares P.P., Nascimento J.H. Abnormal cardiac repolarization in anabolic androgenic steroid users carrying out submaximal exercise testing. Clin. Exp. Pharmacol. Physiol. 2010;37(12):1129–1133. https://doi.org/10.1111/j.1440-1681.2010.05452.x
32. Grandperrin A., Schnell F., Donal E., Galli E., Hedon C., Cazorla O., Nottin S. Specific alterations of regional myocardial work in strength-trained athletes using anabolic steroids compared to athletes with genetic hypertrophic cardiomyopathy. J. Sport Health. Sci. 2023;12(4):477–485. https://doi.org/10.1016/j.jshs.2022.07.004
33. D’Andrea A., Radmilovic J., Caselli S., Carbone A., Scarafile R., Sperlongano S., Tocci G., et al. Left atrial myocardial dysfunction after chronic abuse of anabolic androgenic steroids: a speckle tracking echocardiography analysis. Int. J. Cardiovasc. Imaging. 2018;34(10):1549–1559. https://doi.org/10.1007/s10554-018-1370-9
34. Akcakoyun M., Alizade E., Gundogdu R., Bulut M., Tabakci M.M., Acar G., et al. Long-term anabolic androgenic steroid use is associated with increased atrial electromechanical delay in male bodybuilders. Biomed. Res. Int. 2014;2014:451520. https://doi.org/10.1155/2014/451520
35. Sullivan M.L., Martinez C.M., Gallagher E.J. Atrial fibrillation and anabolic steroids. J. Emerg. Med. 1999;17(5):851–857. https://doi.org/10.1016/s0736-4679(99)00095-5
36. Geyer H., Braun H., Burke L.M., Stear S.J., Castell L.M. A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance – Part 22. Br. J. Sports Med. 2011;45(9):752–754. https://doi.org/10.1136/bjsports-2011-090180
37. Balasubramanian A., Thirumavalavan N., Srivatsav A., Yu J., Lipshultz L.I., Pastuszak A.W. Testosterone Imposters: An Analysis of Popular Online Testosterone Boosting Supplements. J Sex Med. 2019;16:203–212. https://doi.org/10.1016/j.jsxm.2018.12.008
38. Morgado A., Tsampoukas G., Sokolakis I., Schoentgen N., Urkmez A., Sarikaya S. Do “testosterone boosters” really increase serum total testosterone? A systematic review. Int J Impot Res. 2023. https:// doi.org/ 10.1038/s41443-023-00763-9
39. Deligiannis A.P., Kouidi E.I. Cardiovascular adverse effects of doping in sports. Hellenic J. Cardiol. 2012;53(6):447–457.
40. Perry J.C., Schuetz T.M., Memon M.D., Faiz S., Cancarevic I. Anabolic Steroids and Cardiovascular Outcomes: The Controversy. Cureus. 2020;12(7):e9333. https://doi.org/10.7759/cureus.9333
41. Geyer H., Parr M.K., Mareck U., Reinhart U., Schrader Y., Schanzer W. Analysis of non-hormonal nutritional supplements for anabolic-androgenic steroids - results of an international study. Int. J. Sports Med. 2004;25(2):124–129. https://doi.org/10.1055/s-2004-819955
42. Bailey R.L. Current regulatory guidelines and resources to support research of dietary supplements in the United States. Crit. Rev. Food Sci. Nutr. 2020;60(2):298–309. https://doi.org/10.1080/10408398.2018.1524364
Review
For citations:
van der Bijl P., van der Bijl (Jr) P. Cardiovascular Effects of Anabolic-Androgenic Steroids in Dietary Supplements. Sports medicine: research and practice. 2023;13(2):77-83. https://doi.org/10.47529/2223-2524.2023.2.11
Views:
626
Email this article 